Dylan Lee

Dr. Dylan Lee


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Allergy
Verified
Journal Article
Closed access
PDF file
HGHaiqing Gao
Haiqing Gao
LMLi Ma
Li Ma
YZYing Zhao
Ying Zhao
AZAiyuan Zhang
Aiyuan Zhang
ZCZihua Chen
Zihua Chen
XLXiaoqun Luo
Xiaoqun Luo

2 May 2026
Verified
Book Chapter
Closed access
TLTina Lee
Tina Lee
LLLuna Lee
Luna Lee
CHChenxiao Hu
Chenxiao Hu
DLDylan Lee
Dylan Lee
This chapter examines the COVID-19 pandemic as a systemic stress test of global health governance, revealing the tensions between state sovereignty, market logic, and multilateral solidarity. It situates pandemic responses within the broader political economy of healthcare, analyzing how intellectual property regimes, supply-chain concentration, and fiscal asymmetries shaped inequities in access to vaccines, diagnostics, and therapeutics. Comparative case studies from the United States, China, and low- and middle-income countries illustrate divergent outcomes arising from variations in state capacity, industrial policy, and social protection. The chapter argues that pandemic resilience requires reimagining health as a global public good, diversifying regional production, reforming intellectual-property frameworks, and embedding equity into international law. Through an integrated analysis of governance, finance, and justice, it proposes a new paradigm of cooperative preparedness grounded in transparency, inclusivity, and sustainable solidarity.

15 April 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
YXYazhou Xing
Yazhou Xing
LLLuna Lee
Luna Lee
QLQinghua Liang
Qinghua Liang
DLDylan Lee
Dylan Lee
The prognostic significance of resection within the T2-FLAIR abnormality in supratentorial glioblastoma remains unclear. While maximal removal of contrast-

2 May 2026
Verified
Book Chapter
Closed access
DLDylan Lee
Dylan Lee
TLTina Lee
Tina Lee
This introduction chapter outlines the conceptual foundations and purpose of the volume The Political Economy of Global Healthcare Industries: States, Markets, and Power. It situates the globalization of healthcare within broader transformations of twenty-first-century capitalism and explains how this volume analyzes healthcare as both an economic system and a moral order. Drawing on political economy, the chapter examines how states, markets, and power interact to shape innovation, regulation, and inequality across global health industries. It highlights key themes of the book—financialization, industrial policy, digitalization, and health security—while establishing the analytical framework linking macroeconomic structures to ethical and institutional dimensions of governance. This chapter provides readers with the theoretical context, scope, and objectives that guide the contributions that follow.

2 January 2026
Verified
Book Chapter
Closed access
TLTina Lee
Tina Lee
LLLuna Lee
Luna Lee
CHChenxiao Hu
Chenxiao Hu
NMNicolas Melin
Nicolas Melin
LBLaure C. Bouchez
Laure C. Bouchez
DLDylan Lee
Dylan Lee
This chapter, per the authors, reframes migrant founders as institutional architects who assemble cross-border biomedical pipelines to correct misalignments between national innovation systems and transnational health needs. It introduces Transnational Corrective Innovation and tests six propositions linking dual-regime regulatory fluency, diaspora-anchored finance, early multi-ancestry evidence, capability-based geographic unbundling, privacy-preserving data design, and regulatory reliance to measurable gains in time-to-trial, capital inflection, evidence quality, AI validation, and multi-market access. Using a comparative, de-identified multi-case design (2017–2025) across therapeutics, digital epidemiology, and diagnostics, the chapter operationalizes lean indicators from public, auditable sources. Findings show earlier first-in-human starts, faster institutional financing, fewer representativeness queries, accelerated validation under GDPR and the AI Act, and shorter secondary approval lags, with policy and governance templates distilled for regulators, funders, and universities.

1 January 2026 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
YWyiping Wang
yiping Wang
HZHui Zhu
Hui Zhu
SWShujun Wang
Shujun Wang
DHDanni Hu
Danni Hu
MXMengdan Xu
Mengdan Xu
DLDylan Lee
Dylan Lee
Background: Hepatic encephalopathy (HE) remains a major cause of hospitalization and readmission in cirrhosis and is closely linked to hyperammonemia, microbial dysbiosis, impaired short‐chain fatty acid (SCFA) output, barrier dysfunction, and altered mucosal immunity. We evaluated whether adding a multistrain probiotic to rifaximin was associated with greater neurometabolic improvement and coordinated gut–liver–brain axis changes. Methods: In this prospective, 6‐month, randomized, open‐label, assessor‐blinded, three‐arm controlled study, 61 adults with cirrhosis‐related HE received standard care alone (Con, n = 20), standard care plus rifaximin 550 mg twice daily (Rif, n = 20), or rifaximin plus a multistrain probiotic (1 × 10^9 CFU three times daily; Rif + Pro, n = 21). The main prespecified biochemical readout was serum ammonia at Month 6. A composite HE index incorporating mental status, flapping tremor, number connection test, and ammonia grade was analyzed as a prespecified exploratory neurometabolic score. A predefined mechanistic subset underwent 16S rRNA microbiome profiling, serum SCFA measurement, and fecal secretory IgA (SIgA) testing. Results: Baseline characteristics did not differ across arms. Post‐treatment serum ammonia decreased in a graded pattern (Con 177 ± 43.2, Rif 143 ± 37.5, Rif + Pro 117 ± 34.3 μmol/L), with parallel improvement in the exploratory HE index (10.0 ± 4.9, 5.3 ± 4.7, and 3.7 ± 4.1, respectively). In the mechanistic subset, the microbial community structure differed by treatment (PERMANOVA p = 0.006). Rif + Pro was associated with higher serum propionate, increased Lactobacillus salivarius–associated signal, reduced Bacteroides ovatus–associated signal, and marked fecal SIgA elevation compared with standard care or rifaximin alone. The SIgA–propionate relationship was interpreted as exploratory. Conclusions: Rifaximin plus multistrain probiotics was associated with greater improvement in serum ammonia and exploratory HE severity readouts than rifaximin alone, accompanied by coordinated microbial, metabolic, and mucosal immune changes. These findings support confirmation in adequately powered event‐driven trials with strain‐resolved profiling and targeted metabolomics.